MedTrace Logo

Biodistribution and Dosimetry of 99mTc-Duramycin

NCT05177640 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-01-27

No results posted yet for this study

Summary

Conduct a first-in-human study in healthy volunteers to show safety, biodistribution and dosimetry of \[99mTc\]Duramycin.

Conditions

  • Healthy Volunteers

Interventions

DRUG

99mTc-Duramycin

This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning

Sponsors & Collaborators

  • Molecular Targeting Technologies, Inc.

    collaborator INDUSTRY

  • University Hospital, Antwerp

    lead OTHER

Principal Investigators

  • Sigrid Stroobants, prof · University Hospital, Antwerp

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-17
Primary Completion
2021-12-14
Completion
2021-12-14
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177640 on ClinicalTrials.gov